IN165717B
(bg)
*
|
1986-08-07 |
1989-12-23 |
Battelle Memorial Institute |
|
US5529932A
(en)
*
|
1988-01-28 |
1996-06-25 |
Pharmacia, S.P.A. |
Isolated DNA encoding a plant ribosome inactivating protein from the leaves of saponaria officinalis
|
IL106992A
(en)
*
|
1988-02-11 |
1994-06-24 |
Bristol Myers Squibb Co |
Noble hydrazonic history of anthracycline and methods for their preparation
|
DE4004573A1
(de)
*
|
1989-02-17 |
1990-08-23 |
Tanabe Seiyaku Co |
Neues versuchstier und seine herstellung
|
US5354844A
(en)
*
|
1989-03-16 |
1994-10-11 |
Boehringer Ingelheim International Gmbh |
Protein-polycation conjugates
|
US5576288A
(en)
*
|
1989-04-27 |
1996-11-19 |
The Salk Institute For Biological Studies |
Fibroblast growth factor conjugates
|
US5191067A
(en)
*
|
1989-04-27 |
1993-03-02 |
The Salk Institute For Biological Studies |
Fibroblast growth factor conjugates
|
IL95031A
(en)
|
1989-07-18 |
2007-03-08 |
Amgen Inc |
A method of producing a recombinant human necrotic factor absorber
|
DK0436005T3
(da)
*
|
1989-07-20 |
1995-07-03 |
Sandoz Ltd |
Mærkede polypeptidderivater
|
US5208323A
(en)
*
|
1989-08-10 |
1993-05-04 |
Universite Laval |
Coupling of an anti-tumor to an antibody using glutaraldehyde preactivated anti-tumor agent
|
US6329508B1
(en)
|
1989-09-07 |
2001-12-11 |
Alkermes, Inc. |
Transferrin receptor reactive chimeric antibodies
|
US5977307A
(en)
*
|
1989-09-07 |
1999-11-02 |
Alkermes, Inc. |
Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
|
US5182107A
(en)
*
|
1989-09-07 |
1993-01-26 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
|
US5527527A
(en)
*
|
1989-09-07 |
1996-06-18 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
|
US5672683A
(en)
*
|
1989-09-07 |
1997-09-30 |
Alkermes, Inc. |
Transferrin neuropharmaceutical agent fusion protein
|
US5632988A
(en)
*
|
1989-10-23 |
1997-05-27 |
Schering Corporation |
Polypeptide inhibitors of gamma interferon
|
ATE200493T1
(de)
*
|
1990-03-02 |
2001-04-15 |
Boston Medical Ct Corp |
Verbesserte chimäre toxine
|
US6552170B1
(en)
|
1990-04-06 |
2003-04-22 |
Amgen Inc. |
PEGylation reagents and compounds formed therewith
|
US5137877B1
(en)
*
|
1990-05-14 |
1996-01-30 |
Bristol Myers Squibb Co |
Bifunctional linking compounds conjugates and methods for their production
|
DK0485563T3
(da)
*
|
1990-05-30 |
1995-03-20 |
Deutsches Krebsforsch |
Polyethersubstituerede antitumormidler
|
IL98528A0
(en)
*
|
1990-06-21 |
1992-07-15 |
Merck & Co Inc |
Pharmaceutical compositions containing hybrid for killing bladder cancer cells
|
EP0537229A1
(en)
*
|
1990-07-05 |
1993-04-21 |
Akzo Nobel N.V. |
Receptor directed-toxin conjugates
|
US5478804A
(en)
*
|
1990-09-19 |
1995-12-26 |
The Salk Institute For Biological Studies |
Treatment of tumorigenic pathophysiological conditions with FGF-cytoxic conjugates
|
EP0510132B1
(en)
*
|
1990-09-28 |
1997-05-14 |
Neorx Corporation |
Polymeric carriers for release of covalently linked agents
|
US5431899A
(en)
*
|
1991-02-04 |
1995-07-11 |
University Of Saskatchewan |
Rotavirus VP6 as a diagnostic and targeting agent
|
US5464753A
(en)
*
|
1991-03-08 |
1995-11-07 |
Univ Illinois |
Purification and manipulation of bone marrow and blood cells on the basis of P-glycoprotein expression
|
WO1992016221A1
(en)
*
|
1991-03-15 |
1992-10-01 |
Synergen, Inc. |
Pegylation of polypeptides
|
AU662155B2
(en)
*
|
1991-05-10 |
1995-08-24 |
Celtrix Pharmaceuticals, Inc. |
Targeted delivery of bone growth factors
|
EP0529175B1
(en)
*
|
1991-07-22 |
1995-08-09 |
BRACCO International B.V. |
Conjugates chelated with paramagnetic metals for targetting
|
NZ244306A
(en)
*
|
1991-09-30 |
1995-07-26 |
Boehringer Ingelheim Int |
Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
|
US5521291A
(en)
*
|
1991-09-30 |
1996-05-28 |
Boehringer Ingelheim International, Gmbh |
Conjugates for introducing nucleic acid into higher eucaryotic cells
|
US5981273A
(en)
*
|
1991-09-30 |
1999-11-09 |
Boehringer Ingelheim Int'l. Gmbh |
Composition comprising an endosomolytic agent for introducing nucleic acid complexes into higher eucaryotic cells
|
US5922859A
(en)
*
|
1992-02-01 |
1999-07-13 |
Boehringer Ingelheim International Gmbh |
Complexes containing nucleic acid which can be taken-up by endocytosis into higher eukaryotic cells
|
EP0563475B1
(en)
*
|
1992-03-25 |
2000-05-31 |
Immunogen Inc |
Cell binding agent conjugates of derivatives of CC-1065
|
US5679350A
(en)
*
|
1992-05-28 |
1997-10-21 |
The University Of Toledo |
Method of delivery of a medicament to a cancer cell using a pathway of plasminogen activator material
|
EP0643584B1
(en)
*
|
1992-05-28 |
2000-03-15 |
The University Of Toledo |
Delivery of a cytotoxic compound to a cancer cell using a pathway of plasminogen activator material
|
EP0646174A1
(en)
*
|
1992-06-16 |
1995-04-05 |
The Whittier Institute For Diabetes And Endocrinology |
Recombinant production of saporin-containing proteins
|
US5393737A
(en)
*
|
1992-08-20 |
1995-02-28 |
Health Research, Inc. |
Cytotoxic drug conjugates for treatment of neoplastic diseases
|
DK0662146T3
(da)
*
|
1992-09-03 |
2000-11-13 |
Univ California |
Dorsalvævpåvirkende faktor og præparat
|
US5466672A
(en)
*
|
1992-12-04 |
1995-11-14 |
Ophidian Pharmaceuticals, Inc. |
Therapeutic use of clostridium difficile toxin A
|
EP0697891B1
(en)
|
1993-05-05 |
2000-03-29 |
Keith Rose |
Polyoxime compounds and their preparation
|
US6174530B1
(en)
|
1993-05-05 |
2001-01-16 |
Gryphon Sciences |
Homogeneous polyoxime compositions and their preparation by parallel assembly
|
US6001364A
(en)
|
1993-05-05 |
1999-12-14 |
Gryphon Sciences |
Hetero-polyoxime compounds and their preparation by parallel assembly
|
US6214345B1
(en)
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
US5502037A
(en)
*
|
1993-07-09 |
1996-03-26 |
Neuromed Technologies, Inc. |
Pro-cytotoxic drug conjugates for anticancer therapy
|
US6491905B1
(en)
*
|
1993-09-14 |
2002-12-10 |
The Uab Research Foundation |
Recombinant bacterial cells for delivery of PNP to tumor cells
|
ATE194920T1
(de)
*
|
1993-09-22 |
2000-08-15 |
Hoechst Ag |
Pro-prodrugs, ihre herstellung und anwendung
|
US5879656A
(en)
*
|
1993-10-26 |
1999-03-09 |
Thomas Jefferson University |
Methods of treating metastatic colorectal cancer with ST receptor binding compounds
|
US7097839B1
(en)
*
|
1993-10-26 |
2006-08-29 |
Thomas Jefferson University |
ST receptor binding compounds and methods of using the same
|
US5962220A
(en)
*
|
1993-10-26 |
1999-10-05 |
Thomas Jefferson University |
Compositions that specifically bind to colorectal cells and methods of using the same
|
EP0657175B1
(en)
*
|
1993-12-09 |
2005-03-02 |
Centro de Inmunologia Molecular |
Vaccine comprising human autologous epidermal growth factor and use thereof
|
US6551618B2
(en)
|
1994-03-15 |
2003-04-22 |
University Of Birmingham |
Compositions and methods for delivery of agents for neuronal regeneration and survival
|
US5911995A
(en)
*
|
1994-08-19 |
1999-06-15 |
Regents Of The University Of Minnesota |
EGF-genistein conjugates for the treatment of cancer
|
US5587459A
(en)
*
|
1994-08-19 |
1996-12-24 |
Regents Of The University Of Minnesota |
Immunoconjugates comprising tyrosine kinase inhibitors
|
DE4433890C2
(de)
*
|
1994-09-22 |
1999-02-18 |
Deutsches Krebsforsch |
Konjugat aus einem Wirkstoff und einem nicht als körperfremd angesehenen, nativen Protein
|
DE69529572T2
(de)
*
|
1994-11-10 |
2003-06-18 |
The University Of Kentucky Research Foundation, Lexington |
Implantierbare wiederauffüllbare vorrichtung mit gesteuerter freisetzung zur verabreichung von arzneistoffen unmittelbar an einen inneren teil des körpers
|
US5766899A
(en)
*
|
1995-02-27 |
1998-06-16 |
Board Of Regents , The University Of Texas System |
Targeted nucleic acid delivery into liver cells
|
US6015555A
(en)
*
|
1995-05-19 |
2000-01-18 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
|
US20030119724A1
(en)
*
|
1995-11-22 |
2003-06-26 |
Ts`O Paul O.P. |
Ligands to enhance cellular uptake of biomolecules
|
DE69626849T2
(de)
*
|
1995-12-22 |
2003-12-24 |
Bristol-Myers Squibb Co., Princeton |
Verzweigte hydrazongruppen enthaltende kuppler
|
US20050025740A1
(en)
*
|
1996-01-05 |
2005-02-03 |
Keith Rose |
Polyoxime compounds and their preparation
|
ES2448467T3
(es)
|
1996-03-12 |
2014-03-14 |
Pg-Txl Company, L.P. |
Profármacos solubles en agua
|
US6441025B2
(en)
*
|
1996-03-12 |
2002-08-27 |
Pg-Txl Company, L.P. |
Water soluble paclitaxel derivatives
|
US6030941A
(en)
*
|
1996-05-01 |
2000-02-29 |
Avi Biopharma, Inc. |
Polymer composition for delivering substances in living organisms
|
TW555765B
(en)
|
1996-07-09 |
2003-10-01 |
Amgen Inc |
Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
|
US5952294A
(en)
*
|
1996-07-31 |
1999-09-14 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Peptidyl prodrugs and methods of making and using the same
|
DE19636889A1
(de)
*
|
1996-09-11 |
1998-03-12 |
Felix Dr Kratz |
Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel
|
US6080383A
(en)
*
|
1997-01-13 |
2000-06-27 |
Rose; Samuel |
Method and composition for the treatment of cancer by the enzymatic conversion of soluble radioactive toxic agents into radioactive toxic precipitates in the cancer
|
WO1998047496A2
(en)
*
|
1997-04-18 |
1998-10-29 |
Access Pharmaceuticals, Inc. |
Polymer-platinum compounds
|
US5965118A
(en)
*
|
1997-04-18 |
1999-10-12 |
Access Pharmaceuticals, Inc. |
Polymer-platinum compounds
|
AU746423B2
(en)
*
|
1997-05-05 |
2002-05-02 |
Mayo Foundation For Medical Education And Research |
Treatment of osteoporosis
|
US6548482B1
(en)
|
1997-05-05 |
2003-04-15 |
Mayo Foundation For Medical Education And Research |
Treatment of osteoporosis
|
US6916790B2
(en)
|
1997-05-05 |
2005-07-12 |
Mayo Foundation For Medical Education And Research |
Treatment of osteoporosis
|
US6030997A
(en)
*
|
1998-01-21 |
2000-02-29 |
Eilat; Eran |
Acid labile prodrugs
|
US6866837B2
(en)
|
1998-06-05 |
2005-03-15 |
Mallinckrodt Inc. |
Radiolabeled peptides for the diagnosis and treatment of breast and prostate tumors and metastases of such tumors
|
JP2002520369A
(ja)
*
|
1998-07-17 |
2002-07-09 |
アメリカ合衆国 |
水溶性薬剤およびその製造方法
|
US6747055B1
(en)
*
|
1998-07-17 |
2004-06-08 |
The United States Of America As Represented By The Department Of Health And Human Services |
Water-soluble drugs and methods for their production
|
GB9904582D0
(en)
*
|
1999-02-26 |
1999-04-21 |
Nycomed Imaging As |
Process
|
US7018654B2
(en)
*
|
1999-03-05 |
2006-03-28 |
New River Pharmaceuticals Inc. |
Pharmaceutical composition containing an active agent in an amino acid copolymer structure
|
US7060708B2
(en)
*
|
1999-03-10 |
2006-06-13 |
New River Pharmaceuticals Inc. |
Active agent delivery systems and methods for protecting and administering active agents
|
US6716452B1
(en)
*
|
2000-08-22 |
2004-04-06 |
New River Pharmaceuticals Inc. |
Active agent delivery systems and methods for protecting and administering active agents
|
US20010041189A1
(en)
*
|
1999-04-13 |
2001-11-15 |
Jingya Xu |
Poly(dipeptide) as a drug carrier
|
US6706892B1
(en)
*
|
1999-09-07 |
2004-03-16 |
Conjuchem, Inc. |
Pulmonary delivery for bioconjugation
|
US20030054977A1
(en)
*
|
1999-10-12 |
2003-03-20 |
Cell Therapeutics, Inc. |
Manufacture of polyglutamate-therapeutic agent conjugates
|
US7067111B1
(en)
*
|
1999-10-25 |
2006-06-27 |
Board Of Regents, University Of Texas System |
Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
|
US20020077290A1
(en)
*
|
2000-03-17 |
2002-06-20 |
Rama Bhatt |
Polyglutamic acid-camptothecin conjugates and methods of preparation
|
ATE469242T1
(de)
*
|
2000-03-27 |
2010-06-15 |
Univ Jefferson |
Zusammensetzungen und methoden zur identifizierung und zum targeting von krebszellen aus dem verdauungskanal
|
BRPI0111220B8
(pt)
*
|
2000-06-02 |
2021-07-27 |
Univ Texas |
conjugados de fármacos com etilenodicisteína (ec)
|
JP2004501664A
(ja)
*
|
2000-06-30 |
2004-01-22 |
ボード・オブ・リージェンツ,ザ・ユニヴァーシティ・オヴ・テキサス・システム |
標的化薬剤送達のための腫瘍組織を浸潤する細胞特異的な内部移行ペプチドの単離
|
US7163918B2
(en)
|
2000-08-22 |
2007-01-16 |
New River Pharmaceuticals Inc. |
Iodothyronine compositions
|
US20020099013A1
(en)
*
|
2000-11-14 |
2002-07-25 |
Thomas Piccariello |
Active agent delivery systems and methods for protecting and administering active agents
|
CZ20031262A3
(en)
*
|
2000-10-16 |
2004-03-17 |
Neopharm, Inc. |
Liposomal formulation of mitoxantrone
|
US8394813B2
(en)
*
|
2000-11-14 |
2013-03-12 |
Shire Llc |
Active agent delivery systems and methods for protecting and administering active agents
|
AU2002217980A1
(en)
|
2000-12-01 |
2002-06-11 |
Cell Works Inc. |
Conjugates of glycosylated/galactosylated peptide
|
CU22999A1
(es)
|
2001-12-04 |
2004-10-12 |
Centro Inmunologia Molecular |
Método de tratamiento de enfermedades malignas e infecciosas crónicas
|
CA2444483A1
(en)
*
|
2001-04-26 |
2002-11-07 |
Board Of Regents, The University Of Texas System |
Diagnostic imaging compositions, their methods of synthesis and use
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
ES2334494T5
(es)
|
2001-05-11 |
2013-05-29 |
Ludwig Institute For Cancer Research Ltd. |
Proteínas de unión específicas y usos de las mismas
|
WO2002094271A1
(en)
*
|
2001-05-15 |
2002-11-28 |
Faulk Pharmaceuticals, Inc. |
Targeted delivery of bioaffecting compounds for the treatment of cancer
|
CA2447335C
(en)
*
|
2001-05-15 |
2011-01-04 |
Faulk Pharmaceuticals, Inc. |
Targeted delivery of drugs for the treatment of viral infections
|
CA2451511A1
(en)
*
|
2001-06-22 |
2003-01-03 |
The University Of British Columbia |
Antimitotic eleuthesides
|
US7375083B2
(en)
*
|
2003-09-30 |
2008-05-20 |
Shire Llc |
Pharmaceutical compositions for prevention of overdose or abuse
|
US7338939B2
(en)
*
|
2003-09-30 |
2008-03-04 |
New River Pharmaceuticals Inc. |
Abuse-resistant hydrocodone compounds
|
US20070066537A1
(en)
*
|
2002-02-22 |
2007-03-22 |
New River Pharmaceuticals Inc. |
Compounds and compositions for prevention of overdose of oxycodone
|
US20060014697A1
(en)
*
|
2001-08-22 |
2006-01-19 |
Travis Mickle |
Pharmaceutical compositions for prevention of overdose or abuse
|
US7375082B2
(en)
*
|
2002-02-22 |
2008-05-20 |
Shire Llc |
Abuse-resistant hydrocodone compounds
|
US7169752B2
(en)
*
|
2003-09-30 |
2007-01-30 |
New River Pharmaceuticals Inc. |
Compounds and compositions for prevention of overdose of oxycodone
|
US20030109432A1
(en)
*
|
2001-12-10 |
2003-06-12 |
Zuo William W. |
Anticancer polypeptide-metal complexes and compositions, methods of making, and methods of using same
|
RU2196604C1
(ru)
*
|
2001-12-21 |
2003-01-20 |
Северин Евгений Сергеевич |
Полипептид, являющийся аналогом рецепторсвязывающего фрагмента эпидермального фактора роста с 21-й по 31-ю аминокислоту, его конъюгат с доксорубицином и фармацевтическая композиция на его основе
|
US7261875B2
(en)
*
|
2001-12-21 |
2007-08-28 |
Board Of Regents, The University Of Texas System |
Dendritic poly (amino acid) carriers and methods of use
|
EP2266590A3
(en)
|
2002-02-22 |
2011-04-20 |
Shire LLC |
Active agent delivery sytems and methods for protecting and administering active agents
|
AU2003219863C1
(en)
*
|
2002-02-22 |
2009-03-05 |
Shire Llc |
Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances
|
AU2003213259C1
(en)
*
|
2002-02-22 |
2009-07-16 |
Shire Llc |
Use of peptide-drug conjugation to reduce inter-subject variability of drug serum levels
|
US7700561B2
(en)
*
|
2002-02-22 |
2010-04-20 |
Shire Llc |
Abuse-resistant amphetamine prodrugs
|
US7659253B2
(en)
*
|
2002-02-22 |
2010-02-09 |
Shire Llc |
Abuse-resistant amphetamine prodrugs
|
US7105486B2
(en)
*
|
2002-02-22 |
2006-09-12 |
New River Pharmaceuticals Inc. |
Abuse-resistant amphetamine compounds
|
US7815934B2
(en)
|
2002-09-20 |
2010-10-19 |
Alpharma Pharmaceuticals, Llc |
Sequestering subunit and related compositions and methods
|
CA2505537A1
(en)
*
|
2002-11-07 |
2004-05-27 |
Board Of Regents, The University Of Texas System |
Ethylenedicysteine (ec)-drug conjugates, compositions and methods for tissue specific disease imaging
|
EP2530719B1
(en)
|
2003-05-07 |
2020-08-05 |
Indiana University Research and Technology Corporation |
Alloyed semiconductor concentration-gradient quantum dots, use and method of fabricating thereof
|
PT1644019E
(pt)
*
|
2003-05-29 |
2012-05-23 |
Shire Llc |
Compostos de anfetamina resistentes ao abuso
|
US20070087959A1
(en)
*
|
2003-08-19 |
2007-04-19 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Method of inducing biomineralization method of inducing bone regeneration and methods related thereof
|
US7511032B2
(en)
|
2003-10-22 |
2009-03-31 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto
|
WO2005055931A2
(en)
|
2003-12-03 |
2005-06-23 |
University Of Medicine And Dentistry Of New Jersey |
Method of preventing survival of retrovirally cells and of inhibiting formation of infectious retroviruses
|
SI1695991T1
(sl)
*
|
2003-12-10 |
2010-04-30 |
Toudai Tlo Ltd |
Koordinacijski kompleks diaminocikloheksan platine (II) z blok kopolimerom, ki vsebuje segment poli(karboksilne kisline) in antitumorni agens, ki jih vsebuje
|
US9050378B2
(en)
*
|
2003-12-10 |
2015-06-09 |
Board Of Regents, The University Of Texas System |
N2S2 chelate-targeting ligand conjugates
|
DK1732949T3
(da)
|
2004-04-07 |
2010-04-06 |
Rinat Neuroscience Corp |
Fremgangsmåder til behandling af smerter ved knoglekræft ved indgivelse af en nervevækstfaktorantagonist
|
US20060036084A1
(en)
*
|
2004-08-04 |
2006-02-16 |
Lianhua Qu |
Conglomerated semiconductor nanocrystals
|
US8454927B2
(en)
*
|
2004-08-04 |
2013-06-04 |
Crystalplex Corporation |
Alloyed semiconductor nanocrystals
|
AU2006255938B2
(en)
*
|
2005-06-09 |
2011-05-12 |
Nanocarrier Co., Ltd. |
Process for production of polymerized coordination compound of platinum complex
|
WO2007055902A1
(en)
*
|
2005-11-03 |
2007-05-18 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Immunogenic peptides and methods of use for treating and preventing cancer
|
DE602006007177D1
(de)
|
2005-12-05 |
2009-07-16 |
Nitto Denko Corp |
Polyglutamat-aminosäure-konjugate und verfahren
|
US7820174B2
(en)
|
2006-02-24 |
2010-10-26 |
The United States Of America As Represented By The Department Of Health And Human Services |
T cell receptors and related materials and methods of use
|
US9107863B2
(en)
*
|
2006-03-27 |
2015-08-18 |
The Buck Institute For Age Reasearch |
Reagents and methods for cancer treatment and prevention
|
US8758723B2
(en)
|
2006-04-19 |
2014-06-24 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods for cellular imaging and therapy
|
MX2008016372A
(es)
|
2006-06-19 |
2009-05-28 |
Alpharma Inc |
Composiciones farmaceuticas.
|
US8088379B2
(en)
*
|
2006-09-26 |
2012-01-03 |
The United States Of America As Represented By The Department Of Health And Human Services |
Modified T cell receptors and related materials and methods
|
US10925977B2
(en)
|
2006-10-05 |
2021-02-23 |
Ceil>Point, LLC |
Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
|
NZ576467A
(en)
|
2006-10-31 |
2012-03-30 |
Us Gov Health & Human Serv |
Smoothened polypeptides and methods of use
|
US8216565B2
(en)
*
|
2007-01-12 |
2012-07-10 |
The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
GP100-specific T cell receptors and related materials and methods of use
|
JP5276017B2
(ja)
*
|
2007-01-25 |
2013-08-28 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
Egfr変異体仲介性疾患の治療における抗egfr抗体の使用
|
US20080181852A1
(en)
*
|
2007-01-29 |
2008-07-31 |
Nitto Denko Corporation |
Multi-functional Drug Carriers
|
EP2134854B1
(en)
|
2007-03-15 |
2015-04-15 |
Ludwig Institute for Cancer Research Ltd. |
Treatment method using egfr antibodies and src inhibitors and related formulations
|
WO2008124735A2
(en)
*
|
2007-04-10 |
2008-10-16 |
Nitto Denko Corporation |
Multi-functional polyglutamate drug carriers
|
US20080279782A1
(en)
*
|
2007-05-09 |
2008-11-13 |
Nitto Denko Corporation |
Polymers conjugated with platinum drugs
|
ES2430380T3
(es)
|
2007-05-09 |
2013-11-20 |
Nitto Denko Corporation |
Composiciones que incluyen un compuesto hidrófobo y un conjugado de poliaminoácido
|
JP2010526917A
(ja)
*
|
2007-05-09 |
2010-08-05 |
日東電工株式会社 |
複数種の薬物を有するポリグルタミン酸塩複合体及びポリグルタミン酸塩−アミノ酸複合体
|
MX2010001757A
(es)
|
2007-08-14 |
2010-09-14 |
Ludwig Inst Cancer Res |
Anticuerpo monoclonal 175 que activa el receptor egf y derivados y usos del mismo.
|
WO2009029844A1
(en)
*
|
2007-08-31 |
2009-03-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Compounds for inhibiting wip1, prodrugs and compositions thereof, and related methods
|
RU2010137032A
(ru)
*
|
2008-03-06 |
2012-04-20 |
Нитто Денко Корпорейшн (Jp) |
Конъюгаты паклитаксела с полимером и способы лечения рака
|
WO2010075303A1
(en)
|
2008-12-23 |
2010-07-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Splicing factors with a puf protein rna-binding domain and a splicing effector domain and uses of same
|
WO2010075417A1
(en)
|
2008-12-23 |
2010-07-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Survivin specific t cell receptor for treating cancer
|
WO2010088160A1
(en)
|
2009-01-28 |
2010-08-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
T cell receptors and related materials and methods of use
|
WO2010106544A1
(en)
*
|
2009-03-16 |
2010-09-23 |
Rajah Vijay Kumar |
A method and apparatus for - focused resonance nanopermeabilization (forn)
|
WO2010111617A2
(en)
|
2009-03-27 |
2010-09-30 |
Van Andel Research Institute |
Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use
|
US8603814B2
(en)
|
2009-07-20 |
2013-12-10 |
Rutgers The State University Of New Jersey |
Method of inhibiting nonsense-mediated mRNA decay
|
US9849146B2
(en)
|
2009-07-20 |
2017-12-26 |
Rutgers, The State University Of New Jersey |
Inhibition of nonsense mediated mRNA decay by drugs that prevent hypusination of eukaryotic initiation factor 5A
|
WO2011032099A1
(en)
|
2009-09-11 |
2011-03-17 |
The Board Of Trustees Of The University Of Illinois |
Methods of treating diastolic dysfunction and related conditions
|
US20110076232A1
(en)
*
|
2009-09-29 |
2011-03-31 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
JP5934099B2
(ja)
|
2009-10-01 |
2016-06-15 |
アメリカ合衆国 |
抗血管内皮増殖因子受容体−2キメラ抗原受容体及び癌の治療のためのその使用
|
US9127079B2
(en)
|
2009-10-16 |
2015-09-08 |
The University Of British Columbia |
Inhibitors of phosphatase and tensin homolog (PTEN) conjugates
|
US20120208762A1
(en)
|
2009-10-27 |
2012-08-16 |
The Board Of Trustees Of The University Of Illinois |
Methods of Diagnosing Diastolic Dysfunction
|
WO2011060218A1
(en)
|
2009-11-13 |
2011-05-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Modulated programmed death ligand-1
|
EP2512503A4
(en)
|
2009-12-18 |
2013-08-21 |
Univ Indiana Res & Tech Corp |
COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR
|
CA2788304A1
(en)
|
2010-01-27 |
2011-08-04 |
Indiana University Research And Technology Corporation |
Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity
|
WO2011116026A2
(en)
|
2010-03-15 |
2011-09-22 |
The Board Of Trustees Of The University Of Illinois |
Inhibitors of beta integrin-g protein alpha subunit binding interactions
|
ES2734889T3
(es)
|
2010-09-21 |
2019-12-12 |
Us Health |
Receptores de células T anti-SSX-2 y materiales relacionados y métodos de uso
|
WO2012054825A1
(en)
|
2010-10-22 |
2012-04-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mage-a3 t cell receptors and related materials and methods of use
|
WO2012087943A2
(en)
|
2010-12-20 |
2012-06-28 |
The Regents Of The University Of Michigan |
Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
|
NZ612297A
(en)
|
2010-12-22 |
2015-10-30 |
Univ Indiana Res & Tech Corp |
Glucagon analogs exhibiting gip receptor activity
|
CN102675422B
(zh)
|
2011-03-15 |
2014-02-05 |
天津托普泰克生物科技有限公司 |
抗乙型肝炎病毒x蛋白多肽药物
|
AU2012240562B2
(en)
|
2011-04-08 |
2016-12-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer
|
CN102746378B
(zh)
|
2011-04-22 |
2014-10-22 |
天津托普泰克生物科技有限公司 |
抗脂肪酸合成酶多肽及其应用
|
EP2718308B1
(en)
|
2011-06-09 |
2017-05-17 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Pseudomonas exotoxin a with less immunogenic t cell and/or b cell epitopes
|
ME02816B
(me)
|
2011-06-22 |
2018-01-20 |
Univ Indiana Res & Tech Corp |
Koagonisti receptora za glukagon/glp-1 receptora
|
PL2755997T3
(pl)
|
2011-09-15 |
2019-01-31 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Receptory komórek T rozpoznające MAGE ograniczone do HLA-A1 lub HLA-CW7
|
EP2755993B1
(en)
|
2011-09-16 |
2017-11-08 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Pseudomonas exotoxin a with less immunogenic b cell epitopes
|
EP2768863B1
(en)
|
2011-10-20 |
2017-09-27 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Anti-cd22 chimeric antigen receptors
|
MX2014003579A
(es)
|
2011-11-17 |
2015-04-10 |
Univ Indiana Res & Tech Corp |
Peptidos de la superfamilia de glucagon que presentan actividad del receptor de glucocorticoide.
|
CA3209571A1
(en)
|
2012-03-23 |
2013-09-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mesothelin chimeric antigen receptors
|
KR102086874B1
(ko)
|
2012-04-11 |
2020-03-10 |
더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 |
B-세포 성숙 항원을 표적화하는 키메라 항원 수용체
|
AU2013266421B2
(en)
|
2012-05-22 |
2017-06-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Murine anti-NY-ESO-1 T cell receptors
|
CN104619350A
(zh)
|
2012-06-14 |
2015-05-13 |
Ambrx公司 |
结合到核受体配体多肽的抗psma抗体
|
AR091478A1
(es)
|
2012-06-21 |
2015-02-04 |
Univ Indiana Res & Tech Corp |
Analogos de glucagon que exhiben actividad de receptor de gip (peptido insulinotropico dependiente de glucosa)
|
AR091477A1
(es)
|
2012-06-21 |
2015-02-04 |
Univ Indiana Res & Tech Corp |
Analogos de glucagon que presentan actividad de receptor de gip
|
JP6461796B2
(ja)
|
2012-09-14 |
2019-01-30 |
アメリカ合衆国 |
Mhcクラスii拘束性mage−a3を認識するt細胞受容体
|
US10072078B2
(en)
|
2012-10-24 |
2018-09-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
M971 chimeric antigen receptors
|
WO2014160627A1
(en)
|
2013-03-25 |
2014-10-02 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-cd276 polypeptides, proteins, and chimeric antigen receptors
|
WO2014205187A1
(en)
|
2013-06-20 |
2014-12-24 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cytolethal distending toxin subunit b conjugated or fused to bacillus anthracis toxin lethal factor
|
AU2014290288B2
(en)
|
2013-07-15 |
2018-03-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-human papillomavirus 16 E6 T cell receptors
|
AU2014329437B2
(en)
|
2013-10-06 |
2018-10-18 |
F. Hoffmann-La Roche Ag |
Modified Pseudomonas exotoxin A
|
SG11201604565WA
(en)
|
2013-12-06 |
2016-07-28 |
Us Health |
Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same
|
CN113046312A
(zh)
|
2014-04-23 |
2021-06-29 |
朱诺治疗学股份有限公司 |
分离、培养和遗传工程改造用于过继治疗的免疫细胞群的方法
|
CN113150112B
(zh)
|
2014-05-29 |
2024-02-06 |
美国卫生和人力服务部 |
抗人乳头瘤病毒16 e7的t细胞受体
|
WO2015187528A1
(en)
|
2014-06-02 |
2015-12-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptors targeting cd-19
|
CN107075483A
(zh)
|
2014-07-15 |
2017-08-18 |
朱诺治疗学股份有限公司 |
用于过继细胞治疗的工程改造的细胞
|
TWI805109B
(zh)
|
2014-08-28 |
2023-06-11 |
美商奇諾治療有限公司 |
對cd19具專一性之抗體及嵌合抗原受體
|
CN117427091A
(zh)
|
2014-10-20 |
2024-01-23 |
朱诺治疗学股份有限公司 |
用于过继细胞治疗中的给药的组合物和方法
|
EP3215164A1
(en)
|
2014-11-03 |
2017-09-13 |
Immures S.r.l. |
T cell receptors
|
NZ769595A
(en)
|
2014-11-05 |
2023-06-30 |
Juno Therapeutics Inc |
Methods for transduction and cell processing
|
AU2015358400B2
(en)
|
2014-12-03 |
2020-09-10 |
Juno Therapeutics, Inc. |
Methods and compositions for adoptive cell therapy
|
KR20170128234A
(ko)
|
2015-01-16 |
2017-11-22 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Ror1에 특이적인 항체 및 키메라 항원 수용체
|
WO2016166568A1
(en)
|
2015-04-16 |
2016-10-20 |
Juno Therapeutics Gmbh |
Methods, kits and apparatus for expanding a population of cells
|
AU2016271147B2
(en)
|
2015-05-29 |
2022-09-08 |
Juno Therapeutics, Inc. |
Composition and methods for regulating inhibitory interactions in genetically engineered cells
|
MA42895A
(fr)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
MA45489A
(fr)
|
2015-10-22 |
2018-08-29 |
Juno Therapeutics Gmbh |
Procédés de culture de cellules, kits et appareil associés
|
BR112018008111A2
(pt)
|
2015-10-22 |
2018-11-06 |
Juno Therapeutics Gmbh |
métodos, kits, agentes e aparelhos para transdução
|
MA45488A
(fr)
|
2015-10-22 |
2018-08-29 |
Juno Therapeutics Gmbh |
Procédés, kits et appareil de culture de cellules
|
US11020429B2
(en)
|
2015-11-05 |
2021-06-01 |
Juno Therapeutics, Inc. |
Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
|
MA44314A
(fr)
|
2015-11-05 |
2018-09-12 |
Juno Therapeutics Inc |
Récepteurs chimériques contenant des domaines induisant traf, et compositions et méthodes associées
|
MA43380A
(fr)
|
2015-12-03 |
2018-10-10 |
Juno Therapeutics Inc |
Récepteurs chimériques modifiés et compositions et procédés associés
|
US11815514B2
(en)
|
2015-12-04 |
2023-11-14 |
Juno Therapeutics, Inc. |
Methods and compositions related to toxicity associated with cell therapy
|
US20190355459A1
(en)
|
2016-03-16 |
2019-11-21 |
Juno Therapeutics, Inc. |
Methods for adaptive design of a treatment regimen and related treatments
|
WO2017161208A1
(en)
|
2016-03-16 |
2017-09-21 |
Juno Therapeutics, Inc. |
Methods for determining dosing of a therapeutic agent and related treatments
|
EP4015536A1
(en)
|
2016-03-22 |
2022-06-22 |
Seattle Children's Hospital (DBA Seattle Children's Research Institute) |
Early intervention methods to prevent or ameliorate toxicity
|
WO2017193107A2
(en)
|
2016-05-06 |
2017-11-09 |
Juno Therapeutics, Inc. |
Genetically engineered cells and methods of making the same
|
CA3025516A1
(en)
|
2016-05-27 |
2017-11-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Flt3-specific chimeric antigen receptors and methods using same
|
CN109562127A
(zh)
|
2016-06-03 |
2019-04-02 |
纪念斯隆-凯特琳癌症中心 |
作为早期治疗选择的过继细胞疗法
|
MA45341A
(fr)
|
2016-06-06 |
2019-04-10 |
Hutchinson Fred Cancer Res |
Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive
|
WO2018005559A1
(en)
|
2016-06-27 |
2018-01-04 |
Juno Therapeutics, Inc. |
Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
|
MA45491A
(fr)
|
2016-06-27 |
2019-05-01 |
Juno Therapeutics Inc |
Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
|
WO2018005759A1
(en)
|
2016-07-01 |
2018-01-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Inhibitor of heme degradation for use to improve antibiotic treatment of mycobacterium tuberculosis infection
|
EP3490585B1
(en)
|
2016-07-29 |
2023-05-17 |
Juno Therapeutics, Inc. |
Immunomodulatory polypeptides and related compositions and methods
|
KR20190062505A
(ko)
|
2016-10-03 |
2019-06-05 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Hpv-특이적 결합 분자
|
WO2018102612A1
(en)
|
2016-12-02 |
2018-06-07 |
Juno Therapeutics, Inc. |
Engineered b cells and related compositions and methods
|
AU2017368333A1
(en)
|
2016-12-03 |
2019-06-13 |
Juno Therapeutics, Inc. |
Methods for determining CAR-T cells dosing
|
EP3548083A1
(en)
|
2016-12-03 |
2019-10-09 |
Juno Therapeutics, Inc. |
Methods for modulation of car-t cells
|
BR112019011207A2
(pt)
|
2016-12-05 |
2019-10-08 |
Juno Therapeutics Inc |
produção de células modificadas para terapia celular adotiva
|
CA3049461A1
(en)
|
2017-01-10 |
2018-07-19 |
Juno Therapeutics, Inc. |
Epigenetic analysis of cell therapy and related methods
|
WO2018134691A2
(en)
|
2017-01-20 |
2018-07-26 |
Juno Therapeutics Gmbh |
Cell surface conjugates and related cell compositions and methods
|
US11850262B2
(en)
|
2017-02-28 |
2023-12-26 |
Purdue Research Foundation |
Compositions and methods for CAR T cell therapy
|
US20230190796A1
(en)
|
2017-04-07 |
2023-06-22 |
Juno Therapeutics, Inc. |
Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
|
EP3615653A1
(en)
|
2017-04-27 |
2020-03-04 |
Juno Therapeutics GmbH |
Oligomeric particle reagents and methods of use thereof
|
CN111225675B
(zh)
|
2017-06-02 |
2024-05-03 |
朱诺治疗学股份有限公司 |
使用过继细胞疗法治疗的制品和方法
|
WO2018223098A1
(en)
|
2017-06-02 |
2018-12-06 |
Juno Therapeutics, Inc. |
Articles of manufacture and methods related to toxicity associated with cell therapy
|
CN109517820B
(zh)
|
2017-09-20 |
2021-09-24 |
北京宇繁生物科技有限公司 |
一种靶向HPK1的gRNA以及HPK1基因编辑方法
|
MA50613A
(fr)
|
2017-10-03 |
2020-08-12 |
Editas Medicine Inc |
Molécules de liaison spécifique à l'hpv
|
SG11202003688PA
(en)
|
2017-11-01 |
2020-05-28 |
Juno Therapeutics Inc |
Process for generating therapeutic compositions of engineered cells
|
SG11202003866QA
(en)
|
2017-11-01 |
2020-05-28 |
Juno Therapeutics Inc |
Chimeric antigen receptors specific for b-cell maturation antigen (bcma)
|
MX2020004608A
(es)
|
2017-11-01 |
2020-10-05 |
Editas Medicine Inc |
Metodos, composiciones y componentes para edicion crispr-cas9 de tgfbr2 en celulas t para inmunoterapia.
|
CA3080509A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Process for producing a t cell composition
|
KR20200074997A
(ko)
|
2017-11-01 |
2020-06-25 |
주노 쎄러퓨티크스 인코퍼레이티드 |
B-세포 성숙 항원에 특이적인 항체 및 키메릭 항원 수용체
|
WO2019090202A1
(en)
|
2017-11-06 |
2019-05-09 |
Editas Medicine, Inc. |
Methods, compositions and components for crispr-cas9 editing of cblb in t cells for immunotherapy
|
CN111989106A
(zh)
|
2017-12-01 |
2020-11-24 |
朱诺治疗学股份有限公司 |
基因工程化细胞的给药和调节方法
|
WO2019113559A2
(en)
|
2017-12-08 |
2019-06-13 |
Juno Therapeutics, Inc. |
Phenotypic markers for cell therapy and related methods
|
JP2021505168A
(ja)
|
2017-12-08 |
2021-02-18 |
ジュノー セラピューティクス インコーポレイテッド |
操作されたt細胞の組成物を製造するための方法
|
EA202091407A1
(ru)
|
2017-12-08 |
2020-10-20 |
Джуно Терапьютикс, Инк. |
Состав бессывороточной среды для культивирования клеток и способы его применения
|
WO2019118937A1
(en)
|
2017-12-15 |
2019-06-20 |
Juno Therapeutics, Inc. |
Anti-cct5 binding molecules and methods of use thereof
|
WO2019144095A1
(en)
|
2018-01-22 |
2019-07-25 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Methods of use for car t cells
|
CN111971059A
(zh)
|
2018-01-31 |
2020-11-20 |
细胞基因公司 |
使用过继细胞疗法和检查点抑制剂的组合疗法
|
WO2019170845A1
(en)
|
2018-03-09 |
2019-09-12 |
Ospedale San Raffaele S.R.L. |
Il-1 antagonist and toxicity induced by cell therapy
|
US20210015869A1
(en)
|
2018-04-05 |
2021-01-21 |
Juno Therapeutics, Inc. |
T cells expressing a recombinant receptor, related polynucleotides and methods
|
US20210017249A1
(en)
|
2018-04-05 |
2021-01-21 |
Juno Therapeutics, Inc. |
Methods of producing cells expressing a recombinant receptor and related compositions
|
JP7410868B2
(ja)
|
2018-04-05 |
2024-01-10 |
ジュノー セラピューティクス インコーポレイテッド |
T細胞受容体およびそれを発現する操作された細胞
|
IL280659B1
(en)
|
2018-08-09 |
2024-07-01 |
Juno Therapeutics Inc |
Processes for creating transgenic cells and their compounds
|
MX2021001519A
(es)
|
2018-08-09 |
2021-05-27 |
Juno Therapeutics Inc |
Metodos para valorar acidos nucleicos integrados.
|
CA3110905A1
(en)
|
2018-08-31 |
2020-03-05 |
Invectys SA |
Chimeric antigen receptors against multiple hla-g isoforms
|
SG11202104355SA
(en)
|
2018-10-31 |
2021-05-28 |
Juno Therapeutics Gmbh |
Methods for selection and stimulation of cells and apparatus for same
|
SG11202103873VA
(en)
|
2018-11-01 |
2021-05-28 |
Juno Therapeutics Inc |
Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d)
|
US20210393690A1
(en)
|
2018-11-01 |
2021-12-23 |
Juno Therapeutics, Inc. |
Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
|
KR20210100624A
(ko)
|
2018-11-06 |
2021-08-17 |
주노 쎄러퓨티크스 인코퍼레이티드 |
유전적으로 조작된 t 세포를 제조하는 방법
|
SG11202105084VA
(en)
|
2018-11-16 |
2021-06-29 |
Juno Therapeutics Inc |
Methods of dosing engineered t cells for the treatment of b cell malignancies
|
CN113710256A
(zh)
|
2018-11-30 |
2021-11-26 |
朱诺治疗学股份有限公司 |
使用过继细胞疗法的治疗方法
|
KR20210110811A
(ko)
|
2018-11-30 |
2021-09-09 |
주노 쎄러퓨티크스 인코퍼레이티드 |
입양 세포 요법에서 b 세포 악성 종양의 투약 및 치료 방법
|
PE20212198A1
(es)
|
2019-01-29 |
2021-11-16 |
Juno Therapeutics Inc |
Anticuerpos y receptores quimericos de antigenos especificos para receptor 1 huerfano tipo receptor tirosina-cinasa (ror1)
|
CA3136618A1
(en)
|
2019-04-10 |
2020-10-15 |
Elevatebio Technologies, Inc. |
Flt3-specific chimeric antigen receptors and methods of using the same
|
KR20220016475A
(ko)
|
2019-05-01 |
2022-02-09 |
주노 쎄러퓨티크스 인코퍼레이티드 |
변형된 tgfbr2 유전자 좌에서 재조합 수용체를 발현하는 세포, 관련 폴리뉴클레오티드 및 방법
|
WO2020223571A1
(en)
|
2019-05-01 |
2020-11-05 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
|
AU2020280105A1
(en)
|
2019-05-22 |
2022-01-20 |
Massachusetts Institute Of Technology |
Circular RNA compositions and methods
|
CN112390894A
(zh)
|
2019-08-12 |
2021-02-23 |
广东东阳光药业有限公司 |
嵌合抗原受体及其应用
|
EP4051402A1
(en)
|
2019-10-30 |
2022-09-07 |
Juno Therapeutics GmbH |
Cell selection and/or stimulation devices and methods of use
|
IL293393A
(en)
|
2019-12-06 |
2022-07-01 |
Juno Therapeutics Inc |
Cell therapy-related toxicity and response-related methods for the treatment of b-cell malignancies
|
JP2023512209A
(ja)
|
2020-01-28 |
2023-03-24 |
ジュノー セラピューティクス インコーポレイテッド |
T細胞形質導入のための方法
|
WO2021207689A2
(en)
|
2020-04-10 |
2021-10-14 |
Juno Therapeutics, Inc. |
Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen
|
EP4150640A1
(en)
|
2020-05-13 |
2023-03-22 |
Juno Therapeutics, Inc. |
Methods of identifying features associated with clinical response and uses thereof
|
CA3179423A1
(en)
|
2020-05-19 |
2021-11-25 |
Robert Alexander WESSELHOEFT |
Circular rna compositions and methods
|
CN116234558A
(zh)
|
2020-06-26 |
2023-06-06 |
朱诺治疗学有限公司 |
条件性地表达重组受体的工程化t细胞、相关多核苷酸和方法
|
JP2023549780A
(ja)
|
2020-11-04 |
2023-11-29 |
ジュノー セラピューティクス インコーポレイテッド |
改変されたインバリアントcd3免疫グロブリンスーパーファミリー鎖遺伝子座からキメラ受容体を発現する細胞ならびに関連するポリヌクレオチドおよび方法
|
KR20230159851A
(ko)
|
2021-03-22 |
2023-11-22 |
주노 쎄러퓨티크스 인코퍼레이티드 |
치료 세포 조성물의 효력을 결정하는 방법
|
WO2022234009A2
(en)
|
2021-05-06 |
2022-11-10 |
Juno Therapeutics Gmbh |
Methods for stimulating and transducing t cells
|
CN115404240A
(zh)
|
2021-05-28 |
2022-11-29 |
上海环码生物医药有限公司 |
制备环形rna的构建体、方法及其用途
|
KR20240112994A
(ko)
|
2021-11-03 |
2024-07-19 |
셀진 코포레이션 |
골수종을 치료하는 데 사용하기 위한 b-세포 성숙 항원에 특이적인 키메라 항원 수용체
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
MX2024005521A
(es)
|
2021-11-08 |
2024-05-21 |
Orna Therapeutics Inc |
Composiciones de nanoparticulas de lipidos para la administracion de polinucleotidos circulares.
|
AU2023223404A1
(en)
|
2022-02-22 |
2024-08-29 |
Juno Therapeutics, Inc. |
Proteinase 3 (pr3) chimeric autoantibody receptor t cells and related methods and uses
|
WO2023220655A1
(en)
|
2022-05-11 |
2023-11-16 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
WO2023230548A1
(en)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Method for predicting response to a t cell therapy
|
WO2023231959A2
(en)
|
2022-05-30 |
2023-12-07 |
Shanghai Circode Biomed Co., Ltd |
Synthetic circular rna compositions and methods of use thereof
|
WO2023250400A1
(en)
|
2022-06-22 |
2023-12-28 |
Juno Therapeutics, Inc. |
Treatment methods for second line therapy of cd19-targeted car t cells
|
WO2024006960A1
(en)
|
2022-06-29 |
2024-01-04 |
Juno Therapeutics, Inc. |
Lipid nanoparticles for delivery of nucleic acids
|
WO2024031091A2
(en)
|
2022-08-05 |
2024-02-08 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for gprc5d and bcma
|
WO2024102762A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
WO2024102730A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and nanoparticle compositions for delivering polynucleotides
|
WO2024129778A2
(en)
|
2022-12-13 |
2024-06-20 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for baff-r and cd19 and methods and uses thereof
|
WO2024129982A2
(en)
|
2022-12-15 |
2024-06-20 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|